Cumberland Pharmaceuticals Inc. - Common Stock (CPIX)
3.0500
+0.2200 (7.77%)
NASDAQ · Last Trade: Mar 23rd, 4:29 PM EDT

Cumberland (CPIX) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 3, 2026
Via Benzinga · September 19, 2025

Cumberland just reported results for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

Cumberland just reported results for the fourth quarter of 2023.
Via InvestorPlace · March 5, 2024
Via Benzinga · May 6, 2025
Via Benzinga · March 21, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · February 19, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 5, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 5, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · February 4, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · February 4, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · February 4, 2025

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.
Via Benzinga · February 4, 2025

Via Benzinga · December 10, 2024

Via Benzinga · December 10, 2024

FDA approval streamlines Acetadote dosing, enhancing safety and efficiency in treating acetaminophen-related liver injury in hospitals worldwide.
Via Benzinga · December 10, 2024



